Alnylam reports positive results from phase 2 study of investigational cemdisiran for the treatment of iga nephropathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny) today announced positive results from a phase 2 study of cemdisiran, an investigational rnai therapeutic targeting the c5 component of the complement pathway, in development in collaboration with regeneron pharmaceuticals for the treatment of adult patients with immunoglobulin a nephropathy (igan). the results were presented at the 18th european meeting on complement in human disease (emchd) being held in bern, swit
ALNY Ratings Summary
ALNY Quant Ranking